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Abstract We recently cloned the major hyaluronidase of human 
plasma, which we termed HYAL1. All hyaluronidase activity 
could be purified from human urine on an anti-HYALl 
monoclonal antibody column. However, urine contains two 
hyaluronidases of 57 kDa and 45 kDa, whereas plasma only 
contains the 57 kDa activity. Microsequencing confirmed that 
both urinary isozymes have N-termini identical to plasma 
hyaluronidase, but a second N-terminus was found in the smaller 
isozyme, apparently derived from the terminal 25 amino acids of 
HYAL1, at the C-terminus. The two polypeptides of the 45 kDa 
isozyme resulting from endoproteolytic cleavage of the 57 kDa 
isoform are presumably linked by disulfide bonds. Sperm 
contains two isozymes of the testicular hyaluronidase, PH-20, 
and the lower molecular weight isozyme is believed to be an 
endoproteolytically processed form of the larger protein. 
Analogously to PH-20, the smaller isozyme of HYAL1 is likely 
to be a proteolytically processed product of the larger isozyme. 
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1. Introduction 
Hyaluronic acid (HA) is a glycosaminoglycan that has a 
key role in the structure and organization of the extracellular 
matrix (ECM) [1]. It is ubiquitous in higher eukaryotes and is 
elevated whenever rapid tissue proliferation and regeneration 
are occurring, such as during embryogenesis, wound healing, 
and malignancy. Until recently, the nature of the enzymes that 
depolymerize HA, the hyaluronidases [2], has been virtually 
unknown. The first eukaryotic hyaluronidase to be cloned was 
from bee venom [3]. It was found that bee venom hyaluroni-
dase has significant homology to a sperm membrane protein, 
PH-20, that had previously been isolated using a monoclonal 
antibody [4]. It was demonstrated subsequently that PH-20 
has hyaluronidase activity [5]. PH-20 m R N A expression is 
restricted to the testis, and it was assumed that PH-20 homo-
logs did not exist in other tissues. Recently we purified and 
cloned the major hyaluronidase activity of human plasma, 
which we termed H Y A L 1 , and observed that the protein is 
homologous to PH-20, with 40% amino acid identity [6]. 
Highest levels of expression of the HYAL1 m R N A were 
found in liver and kidney. The production of monoclonal 
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antibodies was essential for purification of sufficient enzyme 
for microsequencing. Hyaluronidase is present at high specific 
activity in human urine, approximately 100-fold that of hu-
man plasma [7,8]. It has been hypothesized that hyaluronidase 
plays a role in the action of antidiuretic hormone by increas-
ing the permeability of the nephron walls, which have an 
E C M rich in H A [8,9]. However, this has remained contro-
versial [10-12]. As an initial step in exploring this hypothesis 
in greater detail, we wished to determine if urinary hyaluro-
nidase is identical to the plasma enzyme. To answer this ques-
tion, we purified hyaluronidase from human urine using an 
an t i -HYALl monoclonal affinity column and sequenced the 
proteins that bound strongly to the column. 
2. Materials and methods 
2.1. Preparation of the anti-plasma hyaluronidase monoclonal affinity 
column 
For the immunoaffinity purification of hyaluronidase, 3 mg of pu-
rified IgG from a single cell hybridoma clone that immunoprecipitated 
all hyaluronidase activity from human plasma (clone 17E9) was 
coupled to a 1 ml Hi-Trap-NHS-activated column (Pharmacia, Upp-
sala, Sweden) to produce an anti-HYALl affinity column as previ-
ously described [6]. 
2.2. Assays for hyaluronidase activity and protein 
Hyaluronidase activity was measured using a classic colorimetric 
assay [13], a new microtiter-based assay [14], and HA substrate gel 
zymography [15]. All of the assays were standardized to the turbidity 
reducing unit (TRU) with commercial hyaluronidase (Sigma type VI 
hyaluronidase) as a standard. One TRU of hyaluronidase is defined as 
the amount of enzyme that will decrease the turbidity producing ca-
pacity of 0.2 mg HA to that of 0.1 mg HA in 30 min at 37°C [16]. 
Protein concentrations were measured with the detergent-compatible 
Micro BCA assay (Pierce, Rockford, IL, USA). Proteins were visual-
ized with the Pharmacia Phast system on 12.5% SDS-PAGE gels 
according to the manufacturer's instructions. 
2.3. Immunoaffinity purification of human urinary hyaluronidase 
Twenty liters of human urine were collected from laboratory vol-
unteers, concentrated to 1 1 and desalted into PBS on a CH2PRS 
cartridge concentrator fitted with a S3Y10 spiral cartridge (Amicon, 
Beverly, MA, USA). To the concentrated urine, 1% Triton X-100, 1% 
sodium deoxycholate, 1% NP-40, and 0.02% sodium azide were added 
with stirring, followed by centrifugation at lOOOOXg for 1 h to re-
move insoluble material. The urine was filtered through a 0.22 urn 
bottletop filter (Corning Costar Corp., Cambridge, MA, USA) and 
applied to the anti-HYALl column on an FPLC system (Pharmacia) 
at 1 ml/min. The column was then washed with 5 ml of 2 M NaCl in 
1% Triton X-100, followed by 0.1 M Na acetate pH 5.0, 0.1 M NaCl, 
50 mM octylglucoside, and finally with 0.1 M Na citrate, pH 2.7, 0.1 
M NaCl, 50 mM octylglucoside. Fractions of 1.5 ml were collected 
during the washing procedure and assayed for hyaluronidase activity 
as described above. 
2.4. Effect of protease inhibitors on the urinary hyaluronidase 
Because of the large volume involved in the above purification, 
protease inhibitors could not be used. To determine the effects of 
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urinary proteases on hyaluromdase in the urine, 50 ml samples of 
urine were collected directly onto protease inhibitors (Complete pro-
tease inhibitor tablets, Boehringer Mannheim, Germany), and concen-
trated to 2.5 ml on a 8050 Stirred Ultraflltration Cell (Amicon) fitted 
with a YM10 membrane. Assays were then performed as described 
above. 
2.5. Sequence analysis of human urinary hyaluromdase 
Fractions with hyaluronidase activity were concentrated by precip-
itation in 100% acetone at —20°C overnight and resuspended in 40 ul 
Laemmli buffer [17]. The fractions were then separated in a 12% SDS-
PAGE gel on a Mighty Small II system (Hoefer Scientific Instru-
ments, San Francisco, CA, USA). After electrophoresis, the bands 
of protein were excised with a scalpel, extracted, and sequenced by 
Edman degradation. 
2.6. Characterization of urinary hyaluronidase 
Affinity-purified hyaluronidase was diluted 1:500 in 0.1 M citrate-
phosphate buffer, and activity was measured by the colorimetric and 
microtiter assays described above between pH 2.7 and 7.0. Activity 
was measured in the presence and absence of 0.1 M NaCl. 
• : 
Fig. 2. Silver-stained gel of fractions from the monoclonal affinity 
chromatography. Lane 1: Bio-Rad low-range molecular weight 
markers (size on the left); lane 2: 20X concentrated urine; lane 3: 
2 M NaCl wash; lane 4: pH 4.5 wash; lane 5: pH 2.3 wash (frac-
tion 28); lane 6: recombinant HYAL1. 
3. Results 
3.1. Immunoaffinity purification of human urinary 
hyaluronidase 
Levels of hyaluronidase activity in the pooled unconcen-
trated urine were approximately 4 TRU/ml with a protein 
concentration of 70 |xg/ml. This equates to a total amount 
of activity of 8 x 104 TRU in 20000 ml at a specific activity 
of 57 TRU/mg protein. This is approximately 100-fold greater 
than that of human plasma, which has a specific activity of 0.6 
TRU/mg. All of the hyaluronidase present in urine was bound 
to the anti-HYALl column. No activity was detected in the 
2 M NaCl (fractions 12-15, Fig. 1) or the pH 4.5 wash (frac-
tions 19-22, Fig. 1). All of the activity eluted as a very sharp 
peak during the subsequent pH 2.3 wash (fraction 28, Fig. 1). 
62000 TRU were recovered in this fraction, which represents 
a yield of 78%. The SDS-PAGE electrophoresis of column 
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Fig. 1. Monoclonal antibody affinity chromatography of urinary hy-
aluronidase. Protein is represented by the solid line, scale on the left 
(Abs.280, AU = 2.0). Hyaluronidase activity is represented by the 
shaded bar, scale on the right. Fractions of 1.5 ml were collected. 
Fractions 1^ 1 contain the final 6 ml of urine passing through the 
column. Beginning at fraction 12 the column was washed with 2 M 
NaCl, and at fraction 19 with Na acetate pH 4.5. All of the hyalur-
onidase eluted during the Na citrate pH 2.3 wash in fraction 28. 
fraction 28 demonstrates that urine contains five proteins of 
90, 57, 45, 28-30, and 14 kDa that bind to the monoclonal 
antibody (lane 5, Fig. 2). The 90 kDa protein disappeared at 
lower concentrations, or after reduction with 5% p-mercapto-
ethanol, and was probably a dimer of the 45 kDa activity (not 
shown). The size of the other proteins did not change after 
reduction. Only the 90, 57, and 45 kDa proteins possessed 
hyaluronidase activity on substrate gel zymography (Fig. 3). 
The pattern of activity closely resembled that previously re-
ported for rat liver lysosomal hyaluronidase, which consists of 
a doublet of activity on HA zymograms [18]. The smaller 
proteins of 28-30 and 14 kDa did not have hyaluronidase 
activity on substrate gel zymography. These proteins are not 
found in human plasma and their function is unknown. 
3.2. Sequence analysis of urinary hyaluronidase 
The amino acid sequences obtained from the 57 kDa and 45 
kDa isozymes can be seen in Table 1. Sequence A from both 
isozymes is identical to that obtained from human plasma 
hyaluronidase [6]. The sequences did not have significant ho-
mology to PH-20 because HYAL1 and PH-20 are not homol-
ogous at their N-termini [6]. The lower molecular weight iso-
zyme contains a second sequence (sequence B) that is derived 
from the last 25 amino acids of HYAL1 before the C-termi-
nus. This suggests that an internal cleavage had produced a 
smaller isozyme with two N-termini. A hypothetical diagram-
matic representation of this process can be seen in Fig. 4. The 
25 amino acid fragment may be linked to the rest of the 
protein by disulfide bonds between the cysteine residues of 
the fragment and other parts of the protein (Fig. 4). 
Table 1 
Amino acid sequences of the 57 kDa and 45 kDa isozymes 
Isozyme (mol. wt.) N-terminal amino acid sequence 
57 kDa Sequence A: FXGPLLPNRPFTTVWNXNTQW 
45 kDa Sequence A: FXGPLLPNXPFTTVWNA 
Sequence B: VEFKXRXYPGWQAPXXERK 
Amino acid sequences were obtained by Edman degradation of gel-
purified urinary hyaluronidase. Only one sequence was obtained from 
the 57 kDa isozyme, but two different sequences were obtained from 
the smaller 45 kDa isozyme. Sequence B from the smaller isozyme is 
derived from the last 25 amino acids of HYAL1 before the C-termi-
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Fig. 3. Substrate gel zymography of immunoaffinity purified urine 
hyaluronidase. Molecular weight markers are in lanes 1 and 9 (Bio-
Rad low range). 20 X concentrated urine, collected over protease in-
hibitors, and diluted 5X in Laemmli buffer is in lane 2. Two clear-
ings of hyaluronidase activity can be seen at 57 and 45 kDa. An ali-
quot of column fraction 28 was diluted in Laemmli buffer at the 
following concentrations: lane 3: 1/320; 4: 1/160; 5: 1/80; 6: 1/40; 
7: 1/20; 8: 1/10. 20 u.1 was applied per lane. Two clearings of hya-
luronidase activity can be seen at 57 and 45 kDa. At the very high 
concentration in lane 8, an additional band at 90 kDa can be seen. 
3.3. Characterization of human urinary hyaluronidase 
In the absence of NaCl, the urinary hyaluronidase was 
found to have a pH optimum of 3.4. The presence of 0.1 M 
NaCl caused an increase in the pH optimum to pH 3.8, and a 
decrease in overall activity. No activity was detected above 
pH 4.6 (Fig. 5). 
3.4. Effect of protease inhibitors on the urinary hyaluronidase 
Protease inhibitors did not change the characteristics of the 
urine hyaluronidase, including the appearance of the two iso-
zymes of activity on substrate gel zymography (Fig. 3, lane 2). 
This indicates that the larger isoform was not cleaved by non-
specific proteases in the urine, and was likely to have been 
processed prior to voiding, probably in the kidney. 
4. Discussion 
Human urine is known to contain significant levels of hya-
luronidase at high specific activity, 100-fold that of plasma 
[7,8]. However, the nature of the protein bearing the activity 
Unprocessed HYAL1 (57 kDa) 
NH2(A) 
FRGPLLP... 
j 
Disulfide bond 
Emlo-pwteolysis 
Processed HYAL1 (45 kDa) 
N H 2 ( A ) . 
Disulfidc bond 
has been unknown. As an initial step in investigating the 
hypothesis that hyaluronidase plays a role in antidiuresis [9-
12], we wished to determine the relationship of urinary hya-
luronidase to plasma hyaluronidase. Using a monoclonal anti-
body prepared against human plasma hyaluronidase [6], we 
were able to purify all hyaluronidase activity from human 
urine, indicating that all the hyaluronidase activity in urine 
is similar to the plasma enzyme. N-terminal microsequencing 
confirmed that human urinary hyaluronidase was identical to 
the plasma hyaluronidase, HYAL1. Unlike plasma, however, 
urine contains two isozymes of hyaluronidase, with molecular 
weights of 57 and 45 kDa. The lower molecular weight iso-
zyme contains a second N-terminal sequence that was derived 
from the C-terminal 25 amino acids of the protein. This sug-
gests that an internal cleavage had occurred that had created a 
second N-terminus. Because the lower molecular weight iso-
zyme was 12 kDa smaller than the larger form, it would 
appear that approximately 100 internal amino acids had 
been removed by this cleavage reaction. However, the cleav-
age was not prevented if the urine was collected directly onto 
protease inhibitors (Fig. 3, lane 2), and we could detect no 
endopeptidase in human urine that was capable of reducing 
the plasma hyaluronidase from 57 to 45 kDa (data not 
shown). The processing, therefore, was likely to have occurred 
in the kidney prior to voiding. Rat liver lysosomes contain 
two isoforms of hyaluronidase [18], so the lower molecular 
weight isozyme of urinary hyaluronidase may be of lysosomal 
origin. Sperm contains two isozymes of the PH-20 hyaluroni-
dase. The lower molecular weight isozyme of PH-20 is also 
believed to be a proteolytically processed form of the larger 
isozyme [4,19]. The two hyaluronidases PH-20 and HYAL1 
may undergo similar proteolytic processing. This processing 
reaction may be similar to that described for a human chito-
triosidase that has recently been identified [20]. The chitotrio-
sidase is synthesized as a 50 kDa enzymatically active isozyme 
that is predominately secreted, whereas lysosomes contain a 
39 kDa proteolytically processed isozyme [20]. There is struc-
tural similarity between chitin (poly P-JV-acetylglucosamine) 
and HA (poly p-JV-acetylglucosamine and p-glucuronic acid 
disaccharide) [21]. The similarity between the substrates cata-
bolized by the two enzymes supports the hypothesis that the 
two enzymes may be analogously processed. However, the 
-CJ With 0.1M NaCl 
"O Without NaCl 
NII 2 (B) 
Fig. 4. Diagrammatic representation of the putative endoproteolytic 
processing of HYAL1. Unprocessed HYAL1 is shown in the upper 
figure. After endoproteolytic processing, two fragments are gener-
ated that produce two separate N-termini. The 25 amino acid frag-
ment is presumably linked to the rest of the protein by disulfide 
bonds. 
Fig. 5. pH activity curve of urinary hyaluronidase using the micro-
titer assay. Buffer was 0.1 M citrate-phosphate adjusted to the indi-
cated pH, with 1% Triton X-100. Maximal activity is at pH 3.8 in 
the presence of 0.1 M NaCl, and pH 3.4 in the absence of NaCl. 
No activity was detected above pH 4.6. Similar results were ob-
tained with the colorimetric assay. 
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identity of the protease(s) that carries out this reaction is 
currently unknown. 
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